Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Cells are constantly on the move, whether in a developing embryo or metastatic cancer. But how do cells adapt to the new ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, "Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Dr. Thomas Hartung explains how AI and microphysiological systems (MPS) are changing drug safety testing. These ...

After a blistering rise and subsequent fall in the beauty industry, the buzzy ingredient is seeking its second act.

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...